Search clinical trials for: Elbasvir-grazoprevir drug combination

Total 4713 results

University Hospital, Clermont-Ferrand
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis (STREAGER)

Chronic HCV Infection

France
National Cheng-Kung University Hospital
Merck Sharp & Dohme LLC

Completed

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Drug Interaction Potentiation

Taiwan
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC; Institut National de la Santé Et de la Recherche Médicale...

Completed

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 (SAHIV)

HIV | Acute Hepatitis C

France
University Hospital, Toulouse
MSD France

Completed

Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

Chronic Kidney Diseases | Hepatitis C

France
Bayside Health
Merck Sharp & Dohme LLC; Austin Hospital, Melbourne Australia

Withdrawn

HepATocellular Cancer Hcv Therapy Study (HATCHeT)

Hepatocellular Carcinoma | Hepatitis C | Hepatoma | Liver Cell Carcinoma
Erasmus Medical Center

Completed

Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV (DAHHS-2)

Hepatitis C | Human Immunodeficiency Virus | Acute Hepatitis C

Netherlands, Belgium
Institute Of Cardiology & Internal Diseases, Kazakhstan
Merck Sharp & Dohme LLC; Synergy Research Group

Unknown

Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

Metabolic Syndrome | Fibrosis, Liver | Cirrhoses, Liver | Chronic Hepatitis C Genotype 1B

Kazakhstan
San Francisco Veterans Affairs Medical Center
Merck Sharp & Dohme LLC

Unknown

Hepatitis C (HCV) Cure and Kidney Health

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

Chronic Hepatitis C Virus
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Hepatitis C
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; Cairo University

Withdrawn

Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 (CLEAR-C4)

Hepatitis C Virus Infection, Response to Therapy of

Egypt
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Hepatitis C
Oregon Health and Science University

Completed

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

Substance Abuse, Intravenous | Hepatitis C | Substance Use Disorders

United States
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
King Faisal Specialist Hospital & Research Center
Merck Sharp & Dohme LLC

Unknown

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

Hepatitis C
University of California, Los Angeles
Merck Sharp & Dohme LLC

Withdrawn

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk (HEART-C)

Hepatitis C

United States
University of Florence

Unknown

Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy (CRYOKID)

Hepatitis C | Cryoglobulinaemic Glomerulonephritis
Tel-Aviv Sourasky Medical Center
Merck Sharp & Dohme LLC

Unknown

the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC. (ZEPATIER)

HCV, HCC
Azienda Ospedaliera Universitaria Policlinico Paolo...

Completed

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (EGG-18)

Chronic HCV Hepatitis

Italy
Taichung Veterans General Hospital
Merck Sharp & Dohme LLC

Terminated

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Liver Transplant Infection | Kidney Transplant Infection | Chronic Hepatitis c

Taiwan
Hepa C

Completed

Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

Hepatitis C

Spain
University Hospital, Akershus

Unknown

HCV Treatment in a Low-threshold Clinic (Prindsen)

Hepatitis C | Substance Use Disorders

Norway
Fundacion SEIMC-GESIDA

Withdrawn

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)

HCV

Spain
University of Illinois at Chicago
Merck Sharp & Dohme LLC

Active, not recruiting

Zepatier in Patients With Substance Use

Hepatitis C | Hiv | Substance Use Disorders | Coinfection, HIV

United States
University of Zurich

Completed

Swiss HCVree Trial (HCVree)

Hepatitis C | HIV

Switzerland
Merck Sharp & Dohme LLC

Withdrawn

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Hepatitis C
University of Dundee

Completed

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (ADVANCE)

Hepatitis C

United Kingdom
King Fahad Medical City

Completed

Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 (ELEGANT-4)

Hepatitis C, Chronic

Saudi Arabia
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

Hepatitis C
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Renal Failure

United States
Albert Einstein Healthcare Network
Merck Sharp & Dohme LLC; Davita Clinical Research

Withdrawn

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients (MATCH-D)

Hepatitis C
ANRS, Emerging Infectious Diseases

Completed

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Hepatitis C
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Completed

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (CHROME)

Cardiovascular Diseases | Hepatitis C | Hiv

United States
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV) (USHER)

Heart Failure

United States
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C (HD)

Hepatitis C | Hemodialysis | Nosocomial Infection

United States
Johns Hopkins University
Merck Sharp & Dohme LLC

Completed

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients (EXPANDER-1)

Hepatitis C | End-Stage Renal Disease

United States
The HIV Netherlands Australia Thailand Research...
Merck Sharp & Dohme LLC; Chulalongkorn University

Unknown

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

Compensated Cirrhosis

Thailand
Merck Sharp & Dohme LLC

Completed

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

Hepatitis C
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer

Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 | Stage IIIA Hepatocellular... and other conditions

United States
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Transplanting Hepatitis C Lungs Into Negative Lung Recipients (SHELTER)

Lung Diseases

United States
King's College Hospital NHS Trust
Merck Sharp & Dohme LLC; Hepatitis C Trust

Terminated

ATTIC - Access To Treat in the Community (ATTIC)

Hepatitis C, Chronic

United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
National Taiwan University Hospital
Merck Sharp & Dohme LLC

Completed

EBR/GZR for HCV-1b Patients Receiving Hemodialysis

Hepatitis C

Taiwan
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
Kaohsiung Medical University Chung-Ho Memorial...

Completed

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Hepatitis C, Chronic

Taiwan
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (THINKER)

End Stage Renal Disease

United States
Dallas VA Medical Center
Merck Sharp & Dohme LLC

Terminated

Impact of Hepatitis C Therapy and Bone Health (HCV)

Hepatitis C | Human Immunodeficiency Virus

United States
Raymond T. Chung, MD
Merck Sharp & Dohme LLC

Withdrawn

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Hepatitis C | Cardiac Transplant Disorder

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER)

Hepatitis C Virus
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

Hepatitis C

3

Subscribe